Monday, 16 Sep 2019

You are here

RheumNow Podcast – DESIREABLE Results (5.3.19)

Dr. Jack Cush reviews the latest journal articles and rheumatology news from the past week on RheumNow.com:

  1. FDA has approved Samsung-Bioepsis biosimilar version of etanercept - Eticovo (etanercept-ykro), approved in other countries under names Benepali and Brenzys. Approval based on 596 RA pt trial w/ 52 wk ACR20 of 80.8% and 81.5% (Enbrel arm) https://t.co/r3q9dQ0Bdb
  2. Benlysta is approved for use in pediatric SLE based on the 80 pt PLUTO trial; 1 yr of PBO vs 10 mg/kg belimumab plus standard therapy. Results presented at ACR2018 shows BEL in pediatric SLE to be safe and effective (SRI4 resp 52.8% vs 43.6%). https://t.co/cjqPaWu92O.     
  3. Analysis of new drug registration trials in RA (1998-2018) shows an increase in placebo responses (significant for ACR50 & ACR70); yet with significant reductions in Disease duration, SJCand DAS28-ESR. Changes in RA? RCTs? expectation bias? https://buff.ly/2USAjC6 
  4. DESIRABLE study from JAPAN Rx 654 (relatively) early, MTX tx RA pts with PBO, or Prolia given q3 or q6 mos. Denosumab lead to significant reductions in Erosion scores, total Xray (not JSN) and increased BMD (vs PBO); no effect on ACR20/50/70. https://t.co/DQrmXYrhAf   
  5. French real-world study of Psoriatic arthritis pts starting apremilast (n 3207) or MTX (n 2736), finds higher discontinuation rates at 1 yr for apremilast (69%) vs MTX (59%) https://t.co/bhPwaPhX23 
  6. Study of 213 RApatients starting MTX. After mean F/U 4.3 yrs and 6288 ALT tests, 7% had ALT elevation; 21% of these were ALT>1.5×ULN. Strongest predictor was a pre‐treatment elevation of ALT (OR 6). 3% permanently stopped MTX due to ALT elevation. https://t.co/ti4ClypXgQ
  7. Study of 14928 Autoimmune/Rheum Dz pts in UK Clinical Practice Research database found the influenza vaccination was not associated with arthritis flare or increase in PCP visits (actually lowered consultas for joint pain in following 90 days) https://t.co/rrwu68g7DM
  8. 8/171 ANCA-Assoc Vasculitis pts had Uncommon manifestations - often seen in PR3+, very young or very old w/ delay in Dx (~12 mos); includes Pancreatitis, unusual pulmonary dz (cystic lung disease; usual interstitial pneumonia) or splenic infarcts https://t.co/UFONWMTYYi   
  9. Nonadherence is Costly for Patients in Pain   
  10. Ideal Outcomes are Seldom Achieved in Gout   
  11. New ACR/AF Guidelines on JIA Polyarthritis and Uveitis 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – The End of Arthritis (9.13.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Do’s and Don’ts in Spondylitis (9.5.19)

Dr. Jack Cush reviews the news and important research published in the last two weeks on RheumNow.com.

Influenza Vaccination Update

FDA's Vaccines and Related Biological Products Advisory Committee met in Silver Spring, Maryland, on March 6 and 22, 2019, to select the influenza viruses for the composition of the influenza vaccine for the 2019-2020 U.S. influenza season.

RheumNow Podcast - I Wanna New Drug (8-30-19)

Dr. Jack Cush vents on choosing new therapies in rheumatoid arthritis.

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.